The role of thromboxane A2 in complement activation-related pseudoallergy

Tamás Gyula Fülöp; Josbert M. Metselaar; Gert Storm; János Szebeni

doi:10.1515/ejnm-2016-0039

The role of thromboxane A₂ in complement activation-related pseudoallergy

Tamás Gyula Fülöp^*, Josbert M. Metselaar, Gert Storm, János Szebeni

^*Corresponding author for this work

Biomaterials Science and Technology

Research output: Contribution to journal › Review article › Academic › peer-review

1 Citation (Scopus)

Abstract

Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A₂ (TXA₂). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

Original language	English
Pages (from-to)	59-67
Number of pages	9
Journal	European journal of nanomedicine
Volume	9
Issue number	2
DOIs	https://doi.org/10.1515/ejnm-2016-0039
Publication status	Published - 1 Apr 2017

Keywords

adverse drug reactions
allergy
anaphylatoxins
anaphylaxis
animal models
hemodynamic changes
hypersensitivity reactions
immune toxicity
pseudoallergy
NLA

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1515/ejnm-2016-0039

Cite this

@article{6e490d0c7ba0486891ae145eaab2d328,

title = "The role of thromboxane A2 in complement activation-related pseudoallergy",

abstract = "Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.",

keywords = "adverse drug reactions, allergy, anaphylatoxins, anaphylaxis, animal models, hemodynamic changes, hypersensitivity reactions, immune toxicity, pseudoallergy, NLA",

author = "F{\"u}l{\"o}p, {Tam{\'a}s Gyula} and Metselaar, {Josbert M.} and Gert Storm and J{\'a}nos Szebeni",

year = "2017",

month = apr,

day = "1",

doi = "10.1515/ejnm-2016-0039",

language = "English",

volume = "9",

pages = "59--67",

journal = "European journal of nanomedicine",

issn = "1662-5986",

publisher = "Walter de Gruyter",

number = "2",

}

TY - JOUR

T1 - The role of thromboxane A2 in complement activation-related pseudoallergy

AU - Fülöp, Tamás Gyula

AU - Metselaar, Josbert M.

AU - Storm, Gert

AU - Szebeni, János

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

AB - Complement activation-related pseudoallergy (CARPA) is a hypersensitivity reaction occurring upon intravenous administration of numerous liposomal therapeutics, other nonbiological complex drugs and biologicals. It has a complex molecular and cellular mechanism that involves the production, actions and interactions of numerous vasoactive mediators in blood, including thromboxane A2 (TXA2). This short review focuses on the latter eicosanoid: Its role in CARPA, effects underlying some of the symptoms and experimental evidence for its rate-limiting role in pulmonary hypertension in pigs. Animal experiments and recent clinical observations suggest that the cyclooxygenase blocker indomethacin may represent an effective new approach to prevent liposome-induced CARPA, lending clinical relevance to better understand the involvement of TXA2 and other eicosanoids in this adverse immune effect.

KW - adverse drug reactions

KW - allergy

KW - anaphylatoxins

KW - anaphylaxis

KW - animal models

KW - hemodynamic changes

KW - hypersensitivity reactions

KW - immune toxicity

KW - pseudoallergy

KW - NLA

UR - http://www.scopus.com/inward/record.url?scp=85017326437&partnerID=8YFLogxK

U2 - 10.1515/ejnm-2016-0039

DO - 10.1515/ejnm-2016-0039

M3 - Review article

AN - SCOPUS:85017326437

SN - 1662-5986

VL - 9

SP - 59

EP - 67

JO - European journal of nanomedicine

JF - European journal of nanomedicine

IS - 2

ER -